Tectonic Therapeutic (TECX) KOL event summary

Introduction and agenda

• The event focused on TX2100, a differentiated anti-angiogenic therapy for HHT and other bleeding disorders, with presentations from company leadership and a KOL, followed by Q&A.

• The agenda included disease overview, unmet needs, scientific rationale, clinical updates, and strategic outlook.

KOL background and credentials

• Dr. Hanny Al-Samkari, Associate Professor at Harvard Medical School and Co-Director of the MGH HHT Center of Excellence, is recognized for advancing clinical trial design and patient advocacy in HHT, and chairs the Cure HHT Global Research and Medical Advisory Board.

Market insights and analysis

• HHT is the second most common genetic bleeding disorder, affecting 1 in 3,800–5,000 people, with about 80,000 affected in the US and 1.6 million worldwide, and no approved therapies.

• The U.S. market is estimated at $2 billion annually, driven by high direct medical costs and frequent hospitalizations, especially for those with anemia.

• Current treatments are inadequate, with significant limitations in tolerability and efficacy of existing anti-angiogenic drugs.

• HHT causes substantial morbidity, including severe bleeding, anemia, and life-threatening complications, with a major impact on quality of life.